Baba 1999.

Methods	DESIGN: ‐parallel‐group ‐3 arm study: a. pranlukast b. seratrodast c. placebo ALLOCATION ‐random (means of allocation un‐specified) BLINDING ‐not specified ‐placebo‐controlled WITHDRAWAL/DROPOUTS ‐not described JADAD's Quality Score = 1 Confirmation of methodology not obtained
Participants	WELL‐CONTROLLED PARTICIPANTS ‐RANDOMISED = 24 Pranlukast = 8/ Control = 9/ Seratrodast = 7 ‐WITHDRAWALS: not described ‐AGE: not described ‐GENDER: not described ‐SEVERITY: not described ‐Baseline FEV1(L) not described ‐ALLERGEN TRIGGERS: not described ‐ASTHMA DURATION: not described ELIGIBILITY CRITERIA ‐AGE: not described ‐well‐controlled on non‐described dose of beclomethasone
Interventions	PROTOCOL: AL + ICS vs same dose ICS (TAPERING ICS dose) DURATION ‐Dose optimisation period: not described ‐Intervention Period: not described TEST GROUP ‐Pranlukast (dose not specified) + beclomethasone (dose not specified) CONTROL GROUP ‐Placebo + beclomethasone (dose not specified) DEVICE ‐not specified ‐CO‐TREATMENT: not specified CRITERIA FOR TAPERING every 4 weeks by 50% the beclomethasone dose MINIMAL DOSE OF ICS ALLOWED: 1/3 to 1/4 of baseline dose
Outcomes	INTENTION‐TO‐TREAT ANALYSES ‐not specified PULMONARY FUNCTION TESTS ‐PEF rates ‐SYMPTOM SCORES not reported FUNCTIONAL STATUS ‐not reported ‐exacerbations ICS DOSE REDUCTION: ‐not reported ‐successful tapering INFLAMMATORY MARKERS: not reported ADVERSE EFFECTS ‐not reported WITHDRAWALS ‐not reported
Notes	‐Abs (1999) ‐funding source (not specified) ‐No contact information provided in abstract. Unable to request confirmation of methodology and data extraction until publication in full‐text of the report ‐User‐defined order: unable to be determined (re: un‐specified mean daily ICS dose )
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	Information not available (Cochrane Grade B)